HFU 22 Header
Sanjiv J. Shah

Sanjiv J. Shah

MD, FAHA, FACC, FASE
Stone Endowed Professor of Medicine
Director of Research, Bluhm Cardiovascular Institute, Northwestern University Feinberg School of Medicine
Director of the Center for Deep Phenotyping and Precision Therapeutics,
Institute of Augmented Intelligence in Medicine, Northwestern University
Director of the Heart Failure with Preserved Ejection Fraction (HFpEF) Program,
Northwestern Memorial Hospital
Chicago, IL, USA
Biography

Dr. Shah is the Stone Endowed Professor of Medicine and Director of Research for the Bluhm Cardiovascular Institute at Northwestern University Feinberg School of Medicine. Dr. Shah is also Director of the Center for Deep Phenotyping and Precision Therapeutics in the Institute or Augmented Intelligence in Medicine at Northwestern University, and he is Director of the Heart Failure with Preserved Ejection Fraction (HFpEF) Program at Northwestern Memorial Hospital in Chicago, Illinois, USA.

Dr. Shah’s research is focused on improving our understanding of the epidemiology, mechanisms, and treatment of HFpEF. Dr. Shah started the first dedicated HFpEF clinical program in the world at Northwestern University in 2007 and has been a leading enroller in clinical trials for HFpEF since that time. Dr. Shah’s research interests also include the study of acquired and genetic risk factors for abnormal cardiac mechanics, and novel machine learning techniques for improved classification and therapeutic targeting of heart failure syndromes. Dr. Shah’s research is currently funded by multiple U.S. National Institutes of Health (NIH) research grants, and he is the principal investigator of the Data Translation Center for the largescale, multi-center NIH HeartShare Program ($25 million program that seeks to accelerate understanding of HFpEF subtypes and treatment targets). Dr. Shah is also a leading heart failure clinical trialists and has been overall principal investigator or steering committee member for > 35 clinical trials. In addition to leadership of pharma heart failure trials, he is also the principal investigator of 2 interventional heart failure trials: Corvia REDUCE LAP-HF II (atrial shunt device) and Axon REBALANCE-HF (greater splanchnic nerve ablation). Dr. Shah has published over 450 original papers, review articles, and editorials. He is the editor of a textbook entitled, “Cardiovascular Genetics and Genomics in Clinical Practice”, and he was an Associate Editor for JAMA Cardiology from 2016-2021. He has also received several awards throughout his career, including the W. Proctor Harvey Teaching Award from the American College of Cardiology, the George Joost MD, teacher-of-the-year award from the Northwestern University Feinberg School of Medicine, and the Feigenbaum Lecturer/Award from the American Society of Echocardiography.

 

Follow @CanHFSociety Along on Twitter

#HFUpdate